MAP2K7 and neuroblastoma: NRASQ61K mutant neuroblastomas were distinctly resistant to SHP2 inhibitors; however, combinations of SHP2 inhibitor with MEK inhibitor were synergistic and reversed resistance to SHP2 inhibition (Valencia-Sama et al., 2020).